NDA 022426 · Takeda Pharms USA
Oseni
Alogliptin Benzoate, Pioglitazone Hydrochloride · Oral
Last checked: Nov 20, 2026Latest source record: Jun 28, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
Jan 25, 2013
Approved uses
3
Original approval plus efficacy supplements
Registered trials
6
1 Phase 3, 0 recruiting
FAERS reports
249
67 serious, 4 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: CONGESTIVE HEART FAILURE Thiazolidinediones, including pioglitazone, which is a component of alogliptin and pioglitazone tablets, cause or exacerbate congestive heart failure in some patients [see Warnings and Precautions (5.1) ] . After initiation of alogliptin and pioglitazone tablets and after dose increases, monitor patients carefully for signs and symptoms of heart failure (e.g., excessive, rapid weight gain, dyspnea and/or edema). If congestive heart failure develops while taking alogliptin and pioglitazone tablets, consider discontinuation of alogliptin and pioglitazone tablets or dosage reduction of pioglitazone in alogliptin and pioglitazone tablets [see Warnings and Precautions (5.1) ] . Alogliptin and pioglitazone tablets are not recommended in patients with symptomatic heart failure [see Warnings and Precautions (5.1) ] . Initiation of alogliptin and pioglitazone...
What it is approved for
From the label in effect Jul 28, 2025.
Alogliptin and pioglitazone tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . Alogliptin and pioglitazone tablets are a combination of alogliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone, a thiazolidinedione agonist of peroxisome proliferator receptor gamma, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: Alogliptin and pioglitazone tablets are not recommended for use in patients with type 1 diabetes mellitus. ( 1 ) Limitations of Use Alogliptin and pioglitazone tablets are not recommended for use in patients with type 1 diabetes mellitus.
Mechanism: Alogliptin and pioglitazone tablets combine two antihyperglycemic agents: alogliptin and pioglitazone. Alogliptin Increased concentrations of the incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are released into the bloodstream from the small intestine in response to meals. These hormones cause insulin release from the pancreatic beta cells in a glucose-dependent manner but are inactivated by the dipeptidyl peptidase-4 (DPP-4) enzyme within minutes. GLP-1 also lowers glucagon secretion from pancreatic alpha cells, reducing...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 12, 2016 Supplement 6 · Efficacy Letter
- Apr 5, 2016 Supplement 3 · Efficacy LabelLetter
- Jan 25, 2013 Original approval · Type 4 - New Combination OtherLabelReview
6 products under this application
- OSENI · ALOGLIPTIN BENZOATE EQ 12.5MG BASE; PIOGLITAZONE HYDROCHLORIDE EQ 45MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
- OSENI · ALOGLIPTIN BENZOATE EQ 12.5MG BASE; PIOGLITAZONE HYDROCHLORIDE EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
- OSENI · ALOGLIPTIN BENZOATE EQ 25MG BASE; PIOGLITAZONE HYDROCHLORIDE EQ 30MG BASE · TABLET, ORAL · Prescription
- OSENI · ALOGLIPTIN BENZOATE EQ 12.5MG BASE; PIOGLITAZONE HYDROCHLORIDE EQ 30MG BASE · TABLET, ORAL · Prescription
- OSENI · ALOGLIPTIN BENZOATE EQ 25MG BASE; PIOGLITAZONE HYDROCHLORIDE EQ 45MG BASE · TABLET, ORAL · Prescription
- OSENI · ALOGLIPTIN BENZOATE EQ 25MG BASE; PIOGLITAZONE HYDROCHLORIDE EQ 15MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Alogliptin Benzoate" as an intervention, any sponsor and status, largest first.
- Phase 3 Alogliptin Pediatric StudyPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT02856113 · 152 participants · Start Oct 14, 2016 · Primary completion Aug 6, 2021
Drug: Alogliptin Benzoate; Placebo · For: Diabetes Mellitus, Type 2
Sites: Little Rock, Arkansas; Los Angeles, California; Palmdale, California · 67 sites in all
Fourth People's Hospital of ShenyangAcademic, hospital or other
NCT02798172 · 81 participants · Start May 2014 · Primary completion Aug 2015
Drug: Alogliptin and Metformin · For: Diabetes Mellitus, Type 2
Yonsei UniversityAcademic, hospital or other
NCT03950505 · 60 participants (planned) · Start May 29, 2020 · Primary completion Dec 2020
Drug: Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment for 24 weeks · For: Non-alcoholic Steatohepatitis; Type2 Diabetes
Sites: Seoul, South Korea
CelltrionIndustry
NCT05363592 · 48 participants · Start Jun 25, 2022 · Primary completion Jul 5, 2022
Drug: CT-L01 12.5/500 mg; Alogliptin Benzoate 12.5 mg and 1 more · For: Healthy
Sites: Daejeon, South Korea
CelltrionIndustry
NCT05363384 · 48 participants · Start Jun 11, 2022 · Primary completion Jun 21, 2022
Drug: CT-L01; Alogliptin Benzoate 25 mg and 1 more · For: Healthy
Sites: Daejeon, South Korea
CelltrionIndustry
NCT05364164 · 24 participants · Start Jul 9, 2022 · Primary completion Jul 19, 2022
Drug: CT-L01 12.5/1,000 mg; CT-L01 12.5/1,000 mg · For: Healthy
Sites: Daejeon, South Korea
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- weight increased21
- drug ineffective11
- fatigue11
- rash11
- blood glucose increased10
- pancreatitis10
- headache9
- vision blurred9
- arthralgia8
- myalgia8
- nausea8
- abdominal pain upper7
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 3 |
| 2014 | 63 |
| 2015 | 103 |
| 2016 | 32 |
| 2017 | 13 |
| 2018 | 9 |
| 2019 | 7 |
| 2020 | 6 |
| 2021 | 5 |
| 2022 | 1 |
| 2024 | 2 |
| 2025 | 4 |
| 2026 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Oseni (Alogliptin Benz/Pioglitazone)
2024 spending
$49K
Beneficiaries
41
64 claims
Per beneficiary
$1,188
$12.79 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $710,649 |
| 2021 | $526,636 |
| 2022 | $394,915 |
| 2023 | $256,634 |
| 2024 | $48,722 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Long-term effects of alogliptin benzoate in hemodialysis patients with diabetes: a 2-year study.
Nakamura Y, Inagaki M, Shimizu T, et al. · Nephron Clin Pract 2013 · Clinical Trial
Sponsor: Takeda
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.